ethanethioic acid S-(2-methylpropyl) ester | 2432-37-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 硫代羧酸及其衍生物
• 英文名称: ethanethioic acid S-(2-methylpropyl) ester
• 英文别名: Isobutylthioacetat；Essigsaeure-i-butyl-thioester；S-Isobutylacetat；Thioessigsaeure-butylester；thioacetic acid S-isobutyl ester；Thioessigsaeure-S-isobutylester；Acetic acid, thio-, S-isobutyl ester；S-(2-methylpropyl) ethanethioate
• CAS: 2432-37-3
• 化学式: C₆H₁₂OS
• 分子量: 132.227
• InChiKey: CKZPJEYIMQJCNA-UHFFFAOYSA-N

物化性质

• 保留指数：
  908;908

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  42.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  异丁硫醇 、 乙酰氯 生成 ethanethioic acid S-(2-methylpropyl) ester
  参考文献：
  名称：

  Cleavage of the Carbon—Sulfur Bond. Rates of Hydrolysis of Some Alkyl Acetates and the Corresponding Thiolacetates in Aqueous Acetone

  摘要：

  DOI：

  10.1021/ja01163a061

文献信息

• TARGETED IDURONATE-2-SULFATASE COMPOUNDS
  申请人：ANGIOCHEM INC.

  公开号：US20150290341A1

  公开（公告）日：2015-10-15

  The present invention is related to a compound that includes a lysosomal enzyme and a targeting moiety, for example, a compound that includes iduronate-2-sulfatase conjugated to Angiopep-2 through a linker formed by specific click chemistry reactions. In certain embodiments, these compounds, owing to the presence of the targeting moiety, can cross the blood-brain barrier or accumulate in the lysosome more effectively than the enzyme alone. The invention also features pharmaceutical compositions containing such compounds and methods for treating lysosomal storage disorders (e.g., mucopolysaccharidosis Type II) using such compounds.

  本发明涉及一种化合物，包括溶酶体酶和靶向基团，例如，包括通过特定点击化学反应形成的连接物将硫酸二糖醛酸酶与Angiopep-2结合在一起的化合物。在某些实施例中，由于存在靶向基团，这些化合物可以比单独的酶更有效地穿过血脑屏障或在溶酶体中积累。该发明还涉及含有这种化合物的药物组合物以及使用这种化合物治疗溶酶体贮积疾病（例如，粘多糖贮积症II型）的方法。
• HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE
  申请人：Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center

  公开号：US20140057914A1

  公开（公告）日：2014-02-27

  The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.

  本发明涉及化合物和方法，可能用作HIF通路活性的抑制剂，用于治疗或预防癌症和其他缺氧介导的疾病。
• SALTS OF HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE
  申请人：Board of Regents, University of Texas System

  公开号：US20150239876A1

  公开（公告）日：2015-08-27

  The present disclosure relates to salts of heterocyclic compounds and methods that inhibit HIF pathway activity. The compounds are designed to treat or prevent cancer and other hypoxia-mediated diseases.

  本公开涉及杂环化合物的盐和抑制HIF通路活性的方法。这些化合物被设计用于治疗或预防癌症和其他缺氧介导的疾病。
• PROTEIN-POLYMER-DRUG CONJUGATES
  申请人：Mersana Therapeutics, Inc.

  公开号：US20160220696A1

  公开（公告）日：2016-08-04

  Auristatin compounds and conjugates thereof are provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L D -D, the protein based recognition-molecule being connected to the polymeric carrier by L P . Each occurrence of D is independently an Auristatin compound. L D and L P are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

  本文提供了Auristatin化合物及其共轭物。该共轭物包括一种基于蛋白质的识别分子（PBRM）和一种聚合物载体，该聚合物载体被取代了一个或多个-LD-D，其中，基于蛋白质的识别分子通过LP连接到聚合物载体上。每个D的出现都是独立的Auristatin化合物。LD和LP是连接治疗剂和PBRM到聚合物载体的连接物。还公开了用于与PBRM共轭形成聚合物-药物-PBRM共轭物的聚合物支架，以及包含共轭物的组合物，其制备方法以及使用共轭物或其组合物治疗各种疾病的方法。
• Cleavage of the Carbon—Sulfur Bond. Rates of Hydrolysis of Some Alkyl Acetates and the Corresponding Thiolacetates in Aqueous Acetone
  作者：Paul N. Rylander、D. Stanley Tarbell

  DOI：10.1021/ja01163a061

  日期：1950.7

表征谱图